BioCentury | Nov 18, 2016
Company News

SciClone deal

...thymalfasin to treat HBV and HCV infection, certain cancers and as a vaccine adjuvant, and DC Bead...
BioCentury | Oct 6, 2014
Finance

3Q14 Stock Wrap-Up: Going big again

...to treat chronic HCV genotype 1 infection BTG plc (LSE:BTG)/SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) China approves DC Bead...
BioCentury | Sep 1, 2014
Clinical News

DC Bead regulatory update

...approved BTG's DC Bead to treat patients with malignant hypervascularized tumors, such as hepatocellular carcinoma (HCC). DC Bead...
...2011. BTG plc (LSE:BTG), London, U.K. Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Product: DC Bead ( E7040...
BioCentury | Sep 1, 2014
Finance

Highlights of weekly biotech stock moves

...CFDA) approved BTG's DC Bead to treat patients with malignant hypervascularized tumors like hepatocellular carcinoma (HCC). DC Bead...
BioCentury | Aug 29, 2014
Company News

China approves BTG's DC Bead

...CFDA) approved BTG's DC Bead to treat patients with malignant hypervascularized tumors like hepatocellular carcinoma (HCC). DC Bead...
BioCentury | Feb 10, 2014
Company News

BTG, Eisai sales and marketing update

...Eisai launched DC Bead in Japan as a device for transcatheter arterial embolization (TAE) therapy in patients...
...treatment materials (STM) category for medical device reimbursement under the Japan's National Health Insurance system. DC Bead...
BioCentury | Aug 12, 2013
Clinical News

DC Bead regulatory update

...Eisai disclosed in its 1Q13 earnings that DC Bead was approved in Japan as a device for...
...as a device for transcatheter arterial embolization (TAE) therapy in patients with hepatocellular carcinoma (HCC). DC Bead...
...Tokyo:4523; Osaka:4523), Tokyo, Japan Product: DC Bead ( LC Bead , Embolic Bead E7040 ) ( Paragon Bead ) (E7040...
BioCentury | May 27, 2013
Company News

BTG, Ekos Corp., Nordion deal

...March 31, 2013. Revenues were £36.1 million ($54.8 million) for BTG's interventional medicines, which includes LC Bead...
BioCentury | Aug 13, 2012
Clinical News

DC Bead: Phase III started

...has rights to DC Bead from Biocompatibles International plc , which BTG acquired in January 2011. DC Bead...
...London, U.K. Eisai Co. Ltd. (Tokyo:4523; Osaka:4523), Tokyo, Japan Product: DC Bead , Paragon Bead ( E7040...
BioCentury | Oct 17, 2011
Analyst Picks & Changes

Analyst picks & changes

...drive significant outperformance." She expects data "imminently" from the Phase II SPACE trial of BTG's DC Bead...
...treat varicose veins and a Phase IIb trial of CytoFab for severe sepsis. BTG markets DC Bead...
Items per page:
1 - 10 of 23